It has been really tricky to identify and appropriately treat vaping-associated lung diseases in the time of COVID-19, said Laura Crotty Alexander, MD, ATSF.
Laura Crotty Alexander, an associate professor of medicine at the University of California, San Diego, discusses how vaping-associated lung diseases have interacted with the COVID-19 pandemic at this year's American Thoracic Society (ATS) meeting. Crotty Alexander is also the section chief of pulmonary critical care at the Veterans Affairs San Diego Healthcare System.
Transcript:
Have there been reports of vaping diseases in the time of COVID-19? How have the 2 conditions interacted?
It has been really tricky to identify and thus appropriately treat vaping-associated lung diseases in the time of COVID-19 because they are so similar to a COVID-19 presentation. So the number one thing we've noticed is delayed diagnosis of people with e-cigarette or vaping product use-associated lung injury (EVALI) or other vaping-associated lung injuries. In general, people with these vaping-associated diseases get about 4 COVID-19 tests before physicians are convinced that they actually do have a vaping-associated disease. It becomes even more important that in the first H&P [history and physical assessment] and especially when a pulmonary critical care person is interviewing a patient to really take a good social history, including that of use of any inhalant. Instead of asking just about smoking, which a vaper of e-cigarettes would interpret as smoking of conventional tobacco, you must ask about use of any kind of inhalant including vaping of nicotine, vaping of THC. Now we have even more words to remember, because now there's dabbing, which is specific for the inhalant use of THC.
We began seeing vaping-related lung diseases as far back as 2008, 2012. Since they became more popular, from 2012 to now, we've seen more and more cases of health effects and particularly lung diseases caused by vaping. It's been really difficult to drill down on what are the chemicals in the aerosols that are causal. Which ones are causing the lipoid pneumonias, which ones are causing the acute eosinophilic pneumonias, which ones are causing the hypersensitivity pneumonias? So again, of all the lung diseases that are out there in the interstitial lung disease/inflammatory lung disease category, almost all of them have been associated with vaping use at this point.
I think as we're moving into a modern era of e-cigarette work, both on a clinical research and the bench side, the EVALI epidemic was helpful in showing that if you take samples from the airway of humans who have suffered a vaping-related lung injury, so if you bronch [perform a bronchoscopy] and do a BAL [bronchoalveolar] lavage, you can actually send that BAL for metabolomic studies to look specifically for the chemicals that are in those airways that shouldn't be there. I think by doing this, and by freely posting these metabolomic profiles and these inflammatory diseases caused by vaping, we might be able to identify some specific chemicals that are particularly toxic to the lungs.
This work has already been started because many people were bronched in the setting of EVALI and those samples were analyzed to identify vitamin E acetate as a primary driver. It's really nice to have these methods already in place, and be looking for these vaping-related lung diseases, so that we can try and get a little bit more specific on what we're looking for. As we create a list of chemicals that we believe are toxic or we prove are toxic, we can take them into mouse models and check to see if they cause a pattern of lung injury like we're seeing in humans. Again, that was done for vitamin E acetate and confirmed that it's directly cytotoxic. Finally, we can then take e-liquids from people suffering from lung injuries, and just look at the e-liquids for those chemical components. Instead of needing to do a bronch and a lavage in the person, we can take their liquid, look for this short list of chemicals that might be driving lung injury, and be able to confirm the diagnosis and specifically tell them why this is happening. So it's a very exciting time in e-cigarette research. I think we're going to make really huge strides in the coming years.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More